Nova Eye Medical Limited (ASX:EYE) is an Adelaide-based medical technology company committed to advanced treatment technologies for the interventional glaucoma market. The company's key products address micro-invasive glaucoma surgery (MIGS), targeting surgeons and hospitals across the US and international markets. Nova Eye Medical is dual-listed on the ASX and has been executing a commercial ramp strategy toward profitability.

Recent Development

On 26 August 2026, Nova Eye Medical provided its audited financial statements for the year ended 30 June 2026. Full-year sales reached A$34.9 million — up 26% in constant currency on the prior year. Revenue for H2 FY26 was A$18.2 million, generating the company's first EBITDA-positive half-year at A$0.2 million. The full-year EBITDA loss was A$2.0 million — an improvement of A$3.5 million on the prior year. The 72% full-year gross Margin demonstrates the high-value nature of the product portfolio. The audited A$ results were confirmed to be in line with the unaudited US$ financial information provided on 29 July 2026. Management reaffirmed FY27 guidance: sales excluding China of US$26-31 million (approximately A$38-45 million), implying 15-37% growth in US$ on FY26, and the company expects to generate positive EBITDA in FY27. Cash on hand and an existing unused Debt Facility totalling A$3.75 million are expected to be sufficient to meet Working Capital requirements and stated guidance targets.

Sector Context

Glaucoma is one of the leading causes of irreversible vision loss globally, affecting an estimated 80 million people. The interventional glaucoma market — where MIGS procedures are performed alongside cataract surgery or as standalone procedures — is growing rapidly as clinical evidence accumulates and surgeon adoption increases. Nova Eye's iTrack product has targeted a specific clinical need in this market, and the company's commercial momentum in H2 FY26 suggests increasing procedure adoption rates among its target surgeon base in the United States and internationally.

Risks and Uncertainties

Nova Eye's path to profitability is dependent on sustaining the H2 FY26 momentum into FY27, where management has guided for positive EBITDA. Sales and Marketing expenses remain the largest cost line at A$19.6 million in FY26, and the pace of surgeon adoption will determine whether these costs can be leveraged effectively as revenue scales. The FY27 guidance excludes China, which suggests ongoing regulatory or market access uncertainty in that geography. The A$3.75 million total Liquidity position is thin relative to the ongoing operating expenditure, and any revenue shortfall could require additional capital.

Catalysts to Watch

The most important near-term milestone is the delivery of positive EBITDA for FY27 — management's own guidance target. Quarterly revenue progress relative to the A$38-45 million FY27 guidance range will be closely monitored. Any update on China market access or regulatory progress could expand the revenue opportunity. International market development outside the US and China will also be a strategic variable for FY27 and beyond.

Closing Note

Nova Eye Medical has reached a genuine inflection point — its first EBITDA-positive half-year in H2 FY26, consistent revenue growth, and guidance for positive full-year EBITDA in FY27. For investors in the interventional glaucoma MedTech space, the combination of a 26% constant-currency revenue growth rate, 72% gross margin, and guidance toward profitability makes Nova Eye a credible story to watch heading into FY27.